Three things to know:
1. CartiHeal has completed enrollment and outcome of interim analysis in an investigational device exemption study of Agili-C, an implant for the treatment of cartilage lesions in joints.
2. Bioventus will provide an additional $5 million to CartiHeal if required to complete the device exemption study.
3. Terms of the deal to acquire CartiHeal were not disclosed.
More articles on biologics:
7D Surgical radiation-free spine surgery system gets European approval
Medtronic to buy Medicrea for 22% above share price: 6 details
2 hospitals with new spine surgery programs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
